Table 2.
Comparisons of the clinicopathologic features between adenocarcinoma with mixed subtypes and other histologic types, including classical adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma in advanced gastric cancer.
| Variable | AMa (%) N = 350 | CAb (%) N = 1736 | MACc (%) N = 324 | SRCCd (%) N = 2195 | P value | AM vs. CA, P value | AM vs. MAC, P value | AM vs. SRCC, P value |
|---|---|---|---|---|---|---|---|---|
| Sex | ||||||||
| Female | 132 (37.7%) | 639 (36.8%) | 95 (29.3%) | 1025 (46.7%) | <0.001 | 0.749 | 0.021 | 0.002 |
| Male | 218 (62.3%) | 1097 (63.2%) | 229 (70.7%) | 1170 (53.3%) | ||||
| Age | ||||||||
| <65 | 155 (44.3%) | 533 (30.7%) | 134 (41.4%) | 1270 (57.9%) | <0.001 | <0.001 | 0.443 | <0.001 |
| ≥65 | 195 (55.7%) | 1203 (69.3%) | 190 (58.6%) | 925 (42.1%) | ||||
| Race | ||||||||
| White | 221 (63.1%) | 1027 (59.2%) | 229 (70.7%) | 1503 (68.5%) | <0.001 | 0.355 | 0.080 | 0.015 |
| Black | 53 (15.1%) | 278 (16.0%) | 45 (13.9%) | 252 (11.5%) | ||||
| Others | 76 (21.7%) | 431 (24.8%) | 50 (15.4%) | 440 (20.0%) | ||||
| Tumor size | ||||||||
| <3 cm | 54 (15.4%) | 321 (18.5%) | 48 (14.8%) | 508 (23.1%) | <0.001 | 0.018 | 0.787 | 0.002 |
| 3–6 cm | 89 (25.4%) | 532 (30.6%) | 90 (27.8%) | 571 (26.0%) | ||||
| ≥6 cm | 207 (59.1%) | 883 (50.9%) | 186 (57.4%) | 1116 (50.8%) | ||||
| Primary site | ||||||||
| Antrum | 100 (28.6%) | 564 (32.5%) | 85 (26.2%) | 550 (25.1%) | <0.001 | 0.038 | <0.001 | 0.543 |
| Pylorus | 42 (12.0%) | 208 (12.0%) | 24 (7.4%) | 266 (12.1%) | ||||
| Body | 61 (17.4%) | 230 (13.2%) | 118 (36.4%) | 404 (18.4%) | ||||
| Cardia | 10 (2.9%) | 87 (5.0%) | 9 (2.8%) | 56 (2.6%) | ||||
| Fundus | 20 (5.7%) | 83 (4.8%) | 14 (4.3%) | 131 (6.0%) | ||||
| Lesser curve | 33 (9.4%) | 228 (13.1%) | 23 (7.1%) | 279 (12.7%) | ||||
| Greater curve | 64 (18.3%) | 253 (14.6%) | 44 (13.6%) | 416 (19.0%) | ||||
| Overlapping/not otherwise specified | 20 (5.7%) | 83 (4.8%) | 7 (2.2%) | 93 (4.2%) | ||||
| T stage | ||||||||
| T2 | 52 (14.9%) | 379 (21.8%) | 58 (17.9%) | 341 (15.5%) | <0.001 | <0.001 | 0.046 | 0.931 |
| T3 | 149 (42.6%) | 866 (49.9%) | 158 (48.8%) | 916 (41.7%) | ||||
| T4 | 149 (42.6%) | 491 (28.3%) | 108 (33.3%) | 938 (42.7%) | ||||
| N stage | ||||||||
| N0 | 113 (32.3%) | 806 (46.4%) | 138 (42.6%) | 854 (38.9%) | <0.001 | <0.001 | 0.002 | 0.063 |
| N1 | 70 (2.0%) | 379 (21.8%) | 77 (23.8%) | 447 (20.4%) | ||||
| N2 | 67 (19.1%) | 274 (15.8%) | 50 (15.4%) | 341 (15.5%) | ||||
| N3 | 100 (28.6%) | 277 (16.0%) | 59 (18.2%) | 553 (25.2%) | ||||
| M stage | ||||||||
| M0 | 295 (84.3%) | 1510 (87.0%) | 272 (84.0%) | 1715 (78.1%) | <0.001 | 0.178 | 0.905 | 0.009 |
| M1 | 55 (15.7%) | 226 (13.0%) | 52 (16.0%) | 480 (21.9%) | ||||
| Surgery | ||||||||
| None | 43 (12.3%) | 175 (10.1%) | 44 (13.6%) | 488 (22.2%) | <0.001 | 0.280 | 0.458 | <0.001 |
| Local tumor destruction | 2 (0.6%) | 11 (0.6%) | 4 (1.2%) | 16 (0.7%) | ||||
| Partial gastrectomy | 200 (57.1%) | 1085 (62.5%) | 194 (59.9%) | 992 (45.2%) | ||||
| Total gastrectomy | 105 (30.0%) | 465 (26.8%) | 82 (25.3%) | 699 (31.8%) | ||||
aAdenocarcinoma with mixed subtypes; bclassical adenocarcinoma; cmucinous adenocarcinoma; dsignet-ring cell carcinoma.